<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004871</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067531, J9950</org_study_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>R01CA067803</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-99072307</secondary_id>
    <secondary_id>NCI-T99-0092</secondary_id>
    <secondary_id>JHOC-J9950</secondary_id>
    <nct_id>NCT00004871</nct_id>
  </id_info>
  <brief_title>Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate (PB, NSC 657802) in Combination With 5-Azacytidine (5-AZA, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white&#xD;
      blood cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate&#xD;
      in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and toxicity of azacitidine in combination with phenylbutyrate in&#xD;
           patients with recurrent, refractory, or untreated acute myeloid leukemia or&#xD;
           myelodysplastic syndrome.&#xD;
&#xD;
        -  Determine the minimal effective pharmacologic dose of azacitidine required to&#xD;
           consistently inhibit DNA methyltransferase in this patient population.&#xD;
&#xD;
        -  Obtain preliminary clinical and/or laboratory data suggesting potential therapeutic&#xD;
           activity of this combination regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose deescalation study of azacitidine.&#xD;
&#xD;
      Patients receive azacitidine subcutaneously daily on days 1-5 and 29-33 followed by&#xD;
      phenylbutyrate IV continuously on days 5-12 and 33-40. Treatment continues for at least 2&#xD;
      courses in the absence of disease progression. Patients with responsive disease may receive&#xD;
      an additional 2 months of therapy.&#xD;
&#xD;
      Cohorts of 3-6 patients receive deescalating doses of azacitidine until the minimal effective&#xD;
      pharmacologic dose (MEPD) is determined. The MEPD is defined as the dose above the dose at&#xD;
      which more than 1 of 6 patients do not meet the target enzyme inhibition of greater than 90%.&#xD;
&#xD;
      Once the MEPD and toxicity have been established for a 5 day schedule, daily dose schedule of&#xD;
      azacitidine is increased to 10, 14, and 21 days, followed by phenylbutyrate for 7 days.&#xD;
      Courses are repeated every 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 32 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium phenylbutyrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed myelodysplastic syndrome (MDS) indicating&#xD;
             one of the following:&#xD;
&#xD;
               -  Refractory anemia (RA)&#xD;
&#xD;
               -  Primary refractory leukopenia or thrombocytopenia with MDS morphology&#xD;
&#xD;
               -  RA with excess blasts (RAEB)&#xD;
&#xD;
               -  RA with ringed sideroblasts (RARS)&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia&#xD;
&#xD;
               -  RAEB in transformation&#xD;
&#xD;
          -  RA or RARS must have at least one of the following:&#xD;
&#xD;
               -  Absolute neutrophil count less than 1,000/mm^3&#xD;
&#xD;
               -  Untransfused hemoglobin less than 8 g/dL&#xD;
&#xD;
               -  Platelet count less than 20,000/mm^3&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
               -  Thrombocytopenia requiring transfusion&#xD;
&#xD;
               -  High risk chromosomal abnormalities&#xD;
&#xD;
          -  Any stage of MDS allowed including:&#xD;
&#xD;
               -  Previously untreated MDS&#xD;
&#xD;
               -  Refractory MDS allowed if failure to achieve remission following prior intensive&#xD;
                  chemotherapy of at least 1 month ago&#xD;
&#xD;
          -  Relapsed, refractory, or untreated acute myeloid leukemia (AML) with the following:&#xD;
&#xD;
               -  WBC less than 30,000/mm^3&#xD;
&#xD;
               -  Stable for at least 2 weeks&#xD;
&#xD;
               -  Unlikely to require cytotoxic therapy during study&#xD;
&#xD;
          -  Untreated AML with poor risk factors for response to standard therapy including:&#xD;
&#xD;
               -  Greater than 60 years old&#xD;
&#xD;
               -  AML occurs in setting of antecedent hematologic disorder&#xD;
&#xD;
               -  High risk chromosomes (e.g., abnormalities of chromosome 5 or 7 or complex&#xD;
                  cytogenetic abnormalities)&#xD;
&#xD;
               -  Medical conditions that preclude cytotoxic chemotherapy as primary therapy&#xD;
&#xD;
          -  Refusal of cytotoxic chemotherapy allowed&#xD;
&#xD;
          -  No clinical evidence of CNS leukostasis or CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL (unless due to hemolysis or Gilbert's disease)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No disseminated intravascular coagulation&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary leukostasis&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 2 weeks prior, during and 3 months&#xD;
             after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy including colony stimulating factors and&#xD;
             recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior hormonal therapy and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven D. Gore, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

